Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Luping, Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437267/
https://www.ncbi.nlm.nih.gov/pubmed/22970367
http://dx.doi.org/10.1155/2012/817297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437267/
https://www.ncbi.nlm.nih.gov/pubmed/22970367
http://dx.doi.org/10.1155/2012/817297

Ejemplares similares